DaVita EBITDA 2010-2024 | DVA

DaVita EBITDA for the quarter ending September 30, 2024 was $0.722B, a 5.48% increase year-over-year.

  • DaVita 2023 EBITDA was 2.348B, a 13.35% increase from 2022.
  • DaVita 2022 EBITDA was 2.072B, a 16.4% decline from 2021.
  • DaVita 2021 EBITDA was 2.478B, a 6.58% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

DaVita EBITDA 2010-2024 | DVA

  • DaVita 2023 EBITDA was 2.348B, a 13.35% increase from 2022.
  • DaVita 2022 EBITDA was 2.072B, a 16.4% decline from 2021.
  • DaVita 2021 EBITDA was 2.478B, a 6.58% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Fresenius SE (FSNUY)$19.5B
Quest Diagnostics (DGX)$18.3B
Encompass Health (EHC)$10.2B
Chemed (CHE)$8.6B
Elanco Animal Health (ELAN)$6.6B
RadNet (RDNT)$6.1B
Option Care Health (OPCH)$3.9B
Amedisys (AMED)$3B
LifeStance Health (LFST)$2.8B
Astrana Health (ASTH)$2.4B
Addus HomeCare (ADUS)$2.3B
U.S Physical Therapy (USPH)$1.5B
Aveanna Healthcare Holdings (AVAH)$1.1B
Pennant (PNTG)$1.1B
Atai Life Sciences (ATAI)$270M
Daxor (DXR)$45M
Psychemedics (PMD)$14M
MEDIROM Healthcare Technologies (MRM)$14M
ATI Physical Therapy (ATIP)$8M
Ontrak (OTRK)$8M
IMAC Holdings (BACK)$1M